Contemporary Pure Laparoscopic vs Robot-Assisted Laparoscopic Radical Nephrectomy: Is the Transition Worth It?

Area of Science:

• Urology
• Minimally Invasive Surgery
• Health Economics

Background:

• The adoption of robotic procedures in surgery is increasing.
• Existing literature suggests robotic procedures are often longer and more expensive than traditional methods.
• Comparative cost and perioperative outcome analyses are crucial for evaluating surgical techniques.

Purpose of the Study:

• To compare the costs and perioperative outcomes of robot-assisted radical nephrectomy (RARN) versus laparoscopic radical nephrectomy (LRN).
• To analyze operative time, blood loss, length of stay, and complication rates.
• To evaluate fixed, variable, and distinct procedural costs associated with each surgical approach.

Main Methods:

• Retrospective review of a 2012-2015 data repository.
• Inclusion of patients undergoing RARN and LRN for renal masses.
• Multivariate analysis controlling for demographic data, comorbidities (Charlson Comorbidity Index), tumor size, and surgeon factors.
• Comparison of perioperative outcomes, oncologic results, and procedural costs.

Main Results:

• No significant differences were found in demographic data, tumor size, preoperative renal function, or malignant histology between LRN (99 cases) and RARN (95 cases).
• LRN patients had a higher comorbidity burden (49.5% vs. 27.3% CCI 2+).
• RARN procedures were longer (mean 32.7 minutes) with higher estimated blood loss (145 mL).
• No differences in length of stay or 90-day complication rates (overall and major) were observed.
• RARN had higher mean procedural costs ($464) and variable costs ($2,310), primarily due to supply costs.
• Fewer 30-day readmissions were noted in the RARN cohort.

Conclusions:

• Robot-assisted radical nephrectomy (RARN) is associated with longer operative times and increased costs, including higher supply and hospitalization expenses, even in experienced centers.
• Despite cost implications, RARN demonstrated comparable perioperative and oncologic outcomes to LRN, with a potential benefit of reduced 30-day readmissions.
• The rising use of RARN necessitates a discussion on cost-effectiveness and potential reimbursement adjustments, especially given the lack of demonstrated superior outcomes.